Fiji's vaccine program reduces childhood death and illness: study

November 25, 2020

Fiji's national vaccine program against pneumonia, a serious lung condition, and rotavirus, a common disease which causes severe diarrhoea and vomiting, has reduced illness and death, new research shows.

The University of Melbourne-led research team, which worked with the Fiji Ministry of Health and Medical Services, says the results underline the importance of vaccines and how they can potentially reduce the impact of viruses such as COVID-19.

Published in The Lancet Regional Health - Western Pacific, the first study looked at Fiji's national rotavirus vaccine program five years after it became the first independent Pacific island country to introduce the vaccine in 2012, and one of few in the Asia-Pacific region.

Morbidity (disease or symptom) and mortality (death) due to rotavirus and all-cause diarrhoea in Fiji fell in those aged two months to 55 years. Rotavirus diarrhoea admissions at the largest hospital among children aged under five fell by 87 per cent.

Lead researcher Professor Fiona Russell, of Murdoch Children's Research Institute and the University of Melbourne, said the findings underlined a wider effort to introduce the vaccine across the Pacific.

"The high uptake means the vaccine was acceptable to the children and their carers," Professor Russell said.

"It showed sustained effectiveness, working in vaccinated children and helping to prevent other members of their household falling ill."

Rotavirus is severely contagious and the most common cause of diarrhoeal disease among infants and young children. It can cause death in extreme cases.

In October 2012, the Fiji Government introduced a rotavirus vaccine into the national immunisation schedule at six and 14 weeks with the Australian Department of Trade and Foreign Affairs' support. National coverage estimates were 85, 91, 94, 93 and 98 per cent in 2013, 2014, 2015, 2016 and 2017, respectively.

"Fiji is the first Pacific island country to show a decline in the burden of rotavirus diarrhoea, and all-cause diarrhoea admissions in people of all ages and mortality in children after rotavirus vaccine introduction," Professor Russell said.

"These reductions were most likely due to the vaccine as rotavirus diarrhoeal outbreaks remained blunted for the five years after vaccine introduction. While improved outpatient management practices may have contributed to the decline in diarrhoea, the temporal relationship to vaccine introduction is compelling."

At the same time in 2012, the Fiji Government introduced a routine infant immunisation schedule for ten-valent pneumococcal conjugate (PCV10) vaccine using three primary doses and no booster dose.

Published in The Lancet Global Health, this study looked at hospital admission rates for children presenting with pneumonia from January 2007 - December 2017 at three Fiji public tertiary hospitals.

Five years after the vaccine was introduced, hospital admissions for all-case pneumonia had fallen for children aged 24-59 months.

Mortality was down by 39 per cent among children aged two-24 months who were admitted to hospital with all-case pneumonia, bronchiolitis, and asthma.

Professor Russell said the second study was the first in a middle-income Asia-Pacific region country to show the effect of PCV10 vaccine and supported its introduction for children in other low and middle-income countries in that region.

"These results provide supportive evidence of the probable benefits of PCV10 in reducing pneumonia in children in Fiji," Professor Russell said.

"Our findings are likely to be helpful for decision making regarding PCV introduction in other low and middle-income countries. Most importantly, for the past four years, these vaccines have been fully funded by the Fiji government."
-end-


University of Melbourne

Related Pneumonia Articles from Brightsurf:

Vaccine proves effective against the most severe type of pneumonia
A pneumococcal vaccine was effective at protecting children in Laos against the most severe type of pneumonia, a new study has found.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

Elderly patients with pneumonia twice as likely to die as those with broken hips, yet underestimate the danger of pneumonia
Elderly patients who are hospitalised with pneumonia are twice as likely to die as those hospitalised with hip fractures -- yet many elderly people fail to accurately assess their risk of pneumonia, concludes research due to be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

Pneumonia recovery reprograms immune cells of the lung
Researchers have determined that after lungs recover from infection, alveolar macrophages (immune cells that live in the lungs and help protect the lungs against infection) are different in multiple ways and those differences persist indefinitely.

Skin and mucous membrane lesions as complication of pneumonia
Painful inflammatory lesions of the skin and mucous membranes may occur in children who develop bacterial pneumonia.

Vaccine reduces likelihood of severe pneumonia
A new study has found severe pneumonia decreases by 35 per cent in children who receive a vaccine against a pneumonia-causing bacteria.

Bacteria in pneumonia attack using bleaching agent
Research shows that bacteria use hydrogen peroxide to weaken the immune system and cause pneumonia.

Many kids with pneumonia get unnecessary antibiotics, chest X-rays
Preschool children with community-acquired pneumonia often receive unnecessary tests and treatment at outpatient clinics and emergency departments, according to a nationally representative study led by Todd Florin, M.D., MSCE, from Ann & Robert H.

Certain psychiatric drugs linked with elevated pneumonia risk
A review of published studies indicates that use of benzodiazepines and benzodiazepine related drugs (BZRDs), which are prescribed to treat various psychiatric diseases, may increase the risk of pneumonia.

Bacterial pneumonia far more dangerous to the heart than viral pneumonia, study finds
Heart complications in patients diagnosed with bacterial pneumonia are more serious than in patients diagnosed with viral pneumonia, according to new research.

Read More: Pneumonia News and Pneumonia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.